Strong Cresemba® (isavuconazole) sales in Europe trigger USD 37.5 million milestone payment to Basilea
The continued growth of Cresemba in Europe reflects both its clinical value and the significant unmet medical need in invasive…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
